Merck & Co.’s Clesrovimab Could Rival Sanofi/AZ’s Beyfortus In RSV

 
• By Jessica Merrill
RSV
Merck released positive data on a monoclonal antibody to protect against RSV • Source: Shutterstock

More from Clinical Trials

More from R&D